after in vitro exposure to recombinant interleukin-2 , 41 of 42 ( 98 % ) of patients ' blood lymphocytes showed a two- to fivefold increase in cytotoxicity against k562 ( a lymphoblastoid human target ) , and 40 of 42 ( 95 % ) demonstrated lymphokine-activated killer cytotoxicity ( greater than 20 % ) to the ovarian carcinoma lines .
C0021756
recombinant interleukin-2
C0086418
human